medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 3

<< Back Next >>

Acta Med 2021; 19 (3)

Breast cancer: an overview

Palmero PJ, Lassard RJ, Juárez ALA, Medina NCA

Language: Spanish
References: 32
Page: 354-360
PDF size: 175.28 Kb.


ABSTRACT

Breast cancer is the most prevalent neoplasm in the female population. In Mexico alone there is an annual incidence of 38.4 per 100,000 women, where the annual cost of each patient is $110,459.00 Mexican pesos, causing a great impact on the health system. Objectives: To describe the etiopathogeny, epidemiology, clinical picture, classification and updated screening of this pathology. Material and methods: A systematic search was carried out in the databases PubMed, Web of Science and EBSCO, using the search terms: breast cancer, pathology, therapy, prevention and control; with the Boolean operator "and". Selecting the articles that had a relevant contribution to this work. We obtained 30 articles as a final sample. Results: The physiopathology involves pathways such as PI3K/AKT and RAS/MEK/ERK, and the presence of hormone receptors. Screening is carried out by clinical examination and mastography, while the definitive diagnosis is made by biopsy techniques. Finally, there are five treatment paths: surgery, radiotherapy, chemotherapy, hormone therapy and biological, each with its specific indications. Conclusions: It is vital the training of medical personnel on this pathology, as well as the development of an efficient strategic plan aimed at early detection.


REFERENCES

  1. Murillo R, Díaz S, Perry F, Poveda C, Piñeros M, Sánchez O et al. Increased breast cancer screening and downstaging in Colombian women: A randomized trial of opportunistic breast-screening. Int J Cancer. 2016; 138 (3): 705-713.

  2. Brouwers PJAM, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J et al. Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. Radiother Oncol. 2018; 128 (3): 434-441.

  3. Pistilli B, Mazouni C, Zingarello A, Faron M, Saghatchian M, Grynberg M et al. Individualized prediction of menses recovery after chemotherapy for early-stage breast cancer: a nomogram developed from UNICANCER PACS04 and PACS05 trials. Clin Breast Cancer. 2019; 19 (1): 63-70.

  4. Segnan N, Minozzi S, Armaroli P, Cinquini M, Bellisario C, González-Lorenzo M et al. Epidemiologic evidence of slow growing, nonprogressive or regressive breast cancer: a systematic review. Int J Cancer. 2016; 139 (3): 554-573.

  5. Ochalek K, Partsch H, Gradalski T, Szygula Z. Do compression sleeves reduce the incidence of arm lymphedema and improve quality of life? Two-year results from a prospective randomized trial in breast cancer survivors. Lymphat Res Biol. 2019; 17 (1): 70-77.

  6. Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019; 30 (11): 1776-1783.

  7. Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018; 124 (14): 2923-2930.

  8. van den Brandt PA, Schulpen M. Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis. Int J Cancer. 2017; 140 (10): 2220-2231.

  9. Fornusek CP, Kilbreath SL. Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses. J Cancer Surviv. 2017; 11 (5): 525-541.

  10. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019; 380 (25): 2395-2405.

  11. Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin Cancer Res. 2017; 23 (3): 666-676.

  12. Inno A, Barni S, Ghidini A, Zaniboni A, Petrelli F. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019; 173 (2): 247-254.

  13. Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016; 7 (40): 66192-66201.

  14. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016; 2 (8): 1030-1037.

  15. Rui L, Guijuan Z, Fengjie B, Min M, Yi M. Eugenol suppresses the development of estrogen receptor-positive precancerous breast lesions and regulates estrogen receptor-related proteins. Acta Medica Mediterr. 2018; 34 (6): 1821-1827.

  16. Garcia D, Spruill LS, Irshad A, Wood J, Kepecs D, Klauber-DeMore N. The value of a second opinion for breast cancer patients referred to a National Cancer Institute (NCI)-designated cancer center with a multidisciplinary breast tumor board. Ann Surg Oncol. 2018; 25 (10): 2953-2957.

  17. Soo MS, Jarosz JA, Wren AA, Soo AE, Mowery YM, Johnson KS et al. Imaging-guided core-needle breast biopsy: impact of meditation and music interventions on patient anxiety, pain, and fatigue. J Am Coll Radiol. 2016; 13 (5): 526-534.

  18. Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G et al. Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst. 2016; 108 (3): djv349.

  19. Chen L, Yang Q, Bao J, Liu D, Huang X, Wang J. Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Sci Rep. 2017; 7 (1): 8479.

  20. Alamdaran SA, Farrokh D, Tavakoli H, Afzali N, Tavakoli M. Core needle breast biopsy with local dental anesthetics. Breast J. 2017; 23 (6): 772-773.

  21. Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA. 2016; 316 (18): 1888-1896.

  22. Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncol. 2020; 21 (9): 1165-1172.

  23. Knight JA, Blackmore KM, Fan J, Malone KE, John EM, Lynch CF et al. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Res. 2018; 20 (1): 23.

  24. Gao JJ, Tan M, Pohlmann PR, Swain SM. HALT-D: a phase II evaluation of crofelemer for the prevention and prophylaxis of diarrhea in patients with breast cancer on pertuzumab-based regimens. Clin Breast Cancer. 2017; 17 (1): 76-78.

  25. Lee O, Ivancic D, Allu S, Shidfar A, Kenney K, Helenowski I et al. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation. Cancer Chemother Pharmacol. 2015; 76 (6): 1235-1246.

  26. White J, Winter K, Kuske RR, Bolton JS, Arthur DW, Scroggins T et al. Long-term cancer outcomes from study NRG oncology/RTOG 9517: a phase 2 study of accelerated partial breast irradiation with multicatheter brachytherapy after lumpectomy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2016; 95 (5): 1460-1465.

  27. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017; 390 (10099): 1048-1060.

  28. Humbert O, Riedinger JM, Vrigneaud JM, Kanoun S, Dygai-Cochet I, Berriolo-Riedinger A et al. 18F-FDG PET-derived tumor blood flow changes after 1 cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer. J Nucl Med. 2016; 57 (11): 1707-1712.

  29. Baumann R, Dunst J. Prognosis in young women with early-stage breast cancer. Strahlenther Onkol. 2016; 192 (10): 737-738.

  30. Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R et al. Tumor characteristics and prognosis in familial breast cancer. BMC Cancer. 2016; 16 (1): 924.

  31. CENETEC [Internet]. NOM-041-SSA2-2011, Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama. [Citado 20/10/2020] Disponible en: http://www.cenetec.salud.gob.mx/descargas/equipoMedico/normas/NOM_041_SSA2_2011.pdf

  32. CENETEC [Internet]. Diagnóstico y tratamiento del cáncer de mama en segundo y tercer nivel de atención. México: Secretaría de Salud; 2009. [Citado 20/10/2020] Disponible en: http://dcs.uqroo.mx/paginas/guiasclinicas/gpc/docs/IMSS-232-09-ER.pdf




2020     |     www.medigraphic.com